Therapeutic effect of maternal molecular hydrogen administration in a rat model of preeclampsia

Abstract

s / Placenta 35 (2014) A1eA112 A78 Conclusion: A novel biomarker to specifically and reliably predict the risk for severe preeclampsia is successfully identified. Further investigations in larger cohorts including populations of other ethnic/genetic backgrounds are necessary. P2.52. THERAPEUTIC EFFECT OF MATERNAL MOLECULAR HYDROGEN ADMINISTRATION IN A RAT MODEL OF PREECLAMPSIA Takafumi Ushida, Yukio Mano, Tomomi Kotani Nagoya university graduate school of medicine, Nagoya city, Japan Objective: Preeclampsia is a pregnancy-specific condition characterized by new-onset hypertension and proteinuria. It is also occasionally related to fetal growth restriction. Some studies suggest that placental oxidative stress plays an important role in the pathogenesis of preeclampsia. Recently, molecular hydrogen (H2) is reported to prevent a variety of diseases associated with oxidative stress in model systems and in human. Here, we studied the efficacy of H2 using a rat model of preeclampsia. Methods:We used thewell-established reduced utero-placental perfusion pressure (RUPP) model of placental ischemia-induced hypertension in rat that mimics features of preeclampsia. RUPP was performed on day 14 of pregnancy, clips were placed around the aorta below the renal arteries and on both the left and right uterine arcade at the ovarian artery. The sham group underwent laparotomy on day 14 of pregnancy without RUPP procedure. Hydrogen-saturated water (HW) was orally administered ad libitum from day 12 to 19 of pregnancy. On day 19, mean arterial pressure (MAP) was measured via carotid catheters, and then fetus and placenta were collected by cesarean section. Results:MAP and urinary protein were significantly increased in the RUPP group compared with the sham group. HW treatment attenuated both MAP and urinary protein (sham 4.73, RUPP 8.14 and RUPP+HW 5.88mg/dL, respectively). RUPP fetuses and placentas were significantly smaller than those of sham group. In the RUPP+HW group, the decrease in fetal and placental weights was improved (fetal weight, sham 2.25, RUPP 1.79 and RUPP+HW 1.98g, respectively; placental weight, sham 0.417, 0.381 and 0.416g, respectively). Conclusion: The prophylactic administration of HWsignificantly attenuated features of preeclampsia. Moreover, fetal growth was also improved. These results suggest that maternal administration of HW could have a potential benefit for the prevention of preeclampsia as a novel intra-uterine therapy. P2.53. PREECLAMPSIA IN PREGNANCIES WITH AND WITHOUT DIABETES; THE ASSOCIATIONS WITH PLACENTAL WEIGHT. A POPULATION STUDY OF 655 842 PREGNANCIES Johanne Dypvik , Ellen Marie Strom-Roum , Camilla Haavaldsen , Lars Johan Vatten , Anne Eskild a,b Department of Obstetrics and Gynecology, Akerhus University Hospital, Lorenskog, Norway; b Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Public Health, Norwegian University of Science and Technology, Trondheim, Norway Objectives: To study whether placental weight in pregnancies with preeclampsia differs by maternal diabetes status? Methods: The study comprised all singleton deliveries in Norway from 1999 through 2010 (n 1⁄4 655 842). Data were obtained from the Medical Birth Registry of Norway. We used z-scores of placental weight to adjust for differences in gestational age at delivery between pregnancies, and we studied the distributions of placental weight z-scores in deciles (tenths) in preeclamptic pregnancies with and without diabetes and in normotensive pregnancies with and without diabetes. Results: In pregnancies with preeclampsia, the mean placental weight was much higher in diabetic pregnancies as compared to non-diabetic pregnancies. Thus, among pregnancies with preeclampsia, diabetic pregnancies were overrepresented in the highest decile of placental weight (28.8%) whereas preeclamptic pregnancies without diabetes were underrepresented in the highest decile of placental weight (9.8%). The enlargement of the placentas in preeclamptic pregnancies with diabetes was also pronounced in pregnancies with preterm delivery, and 30.1% were in the highest decile of placental weight as compared to 5.1% of the preeclamptic pregnancies without diabetes. Conclusion: In pregnancies with preeclampsia, the placenta was large when the mother had concomitant diabetes, whereas in preeclamptic pregnancies without diabetes the placenta was small and smaller than in normotensive pregnancies. This finding suggests that the placental role in preeclampsia may differ by maternal diabetes status. P2.54. ALPHA-1 MICROGLOBULIN AS A POTENTIAL THERAPEUTIC CANDIDATE FOR THE TREATMENT OF PREECLAMPSIA Lena Erlandsson , Ludivine Doridot , Aur elien Ducat , Johann Castille , Jean-Luc Vilotte , Lena Wester Rosenl€ of , Magnus Gram, Bo Akerstr€ om , Daniel Vaiman , Stefan Hansson a a Institution for Clinical Sciences in Lund, Lund University, Department of Obstetrics and Gynecology, Lund, Sweden,; b INSERM U1016, Institute Cochin, Paris, France; c INRA UMR1313, G en etique Animale et Biologie Int egrative, Jouy-en-Josas,